UPDATE 1Amgen cholesterol drug meets goal of 3rd late stage trial
Jan 23 Reuters A cholesterol fighter developed by Amgen Inc from a highly promising new class of medicines significantly lowered levels of "bad" LDL cholesterol in a late stage trial in patients unable...
View ArticleAmgen cholesterol drug meets goal of 3rd late stage trial
Reuters A cholesterol fighter developed by Amgen Inc from a highly promising new class of medicines significantly lowered levels of "bad" LDL cholesterol in a late stage trial in patients unable to...
View ArticleAmgen's Cholesterol Drug Meets Primary Endpoints
Amgen announced that the Phase 3 GAUSS2 Goal Achievement After Utilizing an AntiPCSK9 Antibody in Statin Intolerant Subjects2 trial evaluating evolocumab in patients with high cholesterol who cannot...
View ArticleLipitor Diabetes Litigation May be Centralized Following January 30th Hearing...
Woman who developed Type II diabetes after taking Lipitor have filed lawsuits against Pfizer throughout the United States. Plaintiff attorneys seek to have these hearings centralized before a single...
View ArticleAmgens evolocumab beats Zetia in Ph III GAUSS2 trial for cholesterol reduction
USAbased Amgen the worlds largest independent biotech firm yesterday revealed positive results from the Phase III GAUSS2 Goal Achievement After Utilizing an AntiPCSK9 Antibody in Statin Intolerant...
View ArticleThe Nasty Side of HDL
A recurring theme here when I talk about cardiovascular drug discovery is how poorly we understand human lipidology. Surprise after surprise has followed on efforts to lower LDL andor raise HDL to the...
View ArticleNew Scientific Studies Reveal BergaMet Strikingly Effective for Epidemic...
DENVER Jan. 27 2014 PRNewswire Two separate studies conducted in Italy reveal that a highly concentrated proprietary extract of the Calabrian bergamot fruit 38 citrus bergamot extract...
View ArticleAmgen Announces Positive TopLine Results From Phase 3 LAPLACE2 Trial Of...
THOUSAND OAKS Calif. Jan. 28 2014 PRNewswire &160;Amgen NASDAQAMGN today announced that the Phase 3 LAPLACE2 LDLC Assessment with PCSK9 MonoclonaL Antibody Inhibition Combined with Statin ThErapy2...
View ArticleLipitor Lawsuits Move Forward with Federal Judicial Panel Set to Consider...
The Firm is investigating Lipitor lawsuits on behalf of individuals who developed Type 2 diabetes allegedly due to their use of the statin medication.New York New York PRWEB January 28 2014 For the...
View ArticleAmgen to submit evolocumab apps this year
Amgen Inc. NASDAQAMGN reported data from a fourth Phase III trial evaluating the company's evolocumab AMG 145 and disclosed that it plans to submit global regulatory applications this year for the...
View ArticleAmgen announces topline results from Phase III trial of evolocumab
USAbased Amgen announced that the Phase III LAPLACE2 trial evaluating evolocumab AMG 145 in combination with statin therapy in patients with high cholesterol met its coprimary endpoints.
View ArticleProfits drop for Pfizer
Pfizers turnover fell to $54.6 billion in 2013 a 6 drop yearonyear from $54.7 billion in 2012 but the group deemed this a solid performance overall.Results for the fourth quarter of last year are also...
View ArticleAmgen Cholesterol Drug Meets Endpoints in Phase 3
Amgen announced that the Phase 3 LAPLACE2 LDLC Assessment with PCSK9 MonoclonaL Antibody Inhibition Combined with Statin ThErapy2 trial evaluating evolocumab in coRead more
View ArticleLife An Awfully Big Adventure
Prcis This month Graham Young ruminates on the virtues of smoking too much drinking too much and generally enjoying life too much because healthy living or not life&039;ll kill you in the end M...
View ArticleMore Good News for Novel Drug That Cuts LDL
MedPage Today More phase III results showed that Amgen's investigational PCSK9 inhibitor evolocumab significantly reduced LDL cholesterol within 12 weeks this time in patients who were also taking a...
View ArticleAmgen Announces Positive TopLine Results From Phase 3 RUTHERFORD2 Trial Of...
THOUSAND OAKS Calif. Jan. 30 2014 PRNewswire Amgen NASDAQAMGN today announced that the Phase 3 RUTHERFORD2 RedUction of LDLC with PCSK9 InhibiTion in HEteRozygous Familial HyperchOlesteRolemia Disorder...
View ArticleAmgen reports more evolocumab data
Amgen Inc. NASDAQAMGN reported data on Thursday from the Phase III RUTHERFORD2 trial evaluating evolocumab AMG 145 to treat heterozygous familial hypercholesterolemia heFH in patients who were on a...
View ArticleIntegrative medicine New guidelines recommend statins for 30 million Americans
Breaking news One quarter of Americans reading this article should be on a cholesterollowering statin medicine per new guidelines put out last month by the American Heart Association and the American...
View ArticleEvolucumab Lowers LDLC in Two More Trials
In topline results announced this week the investigational monoclonal antibody PCSK9 met its primary end point in two settings including as an addon to a statin. Heartwire
View ArticleLipitor Lawsuit Hearing Rescheduled for February after Winter Weather...
The attorneys at Bernstein Liebhard LLP are investigating claims by potential Lipitor lawsuit claimants who may have developed Type 2 diabetes after taking the cholesterollowering statin.New York NY...
View Article